Brad Hunter is the director of immune effector cell therapy, medical director of oncology research, and an associate professor at Intermountain Health, where he is a member of the Blood and Marrow Transplant team. He is a native of Salt Lake City and completed medical school at the University of Rochester School of Medicine and Dentistry, where he was inducted into the Alpha Omega Alpha and Gold Humanism in Medicine Societies. He completed internal medicine residency at UCSF, and a fellowship in medical oncology at the combined Dana Farber Cancer Institute/Massachusetts General Hospital program. He was recruited to Intermountain Health to launch their immune effector cell therapy program. In 2023, he launched Intermountain Health’s dedicated Phase I Clinic and remains involved as a co-director.  Beyond significant clinical trial involvement, Dr. Hunter’s research has focused on the optimization of care delivery of stem cell and immune effector cell therapies.